The U.S. Food and Drug Administration approved Eli Lilly’s oral weight-loss medication on April 1, clearing the company to sell orforglipron under the brand name Foundayo. The drug is a once-daily pill intended to act like the GLP-1 hormone that suppresses appetite, the same biological pathway targeted by Lilly’s injectable therapy tirzepatide - marketed as Mounjaro for diabetes and Zepbound for weight loss.
Lilly said Foundayo will begin shipping on April 6 through its LillyDirect distribution program. The company set the price for self-pay customers at $149 per month for the lowest available dose, a price Lilly noted is in line with the competing oral option from Novo Nordisk. After the initial LillyDirect rollout, Foundayo will be made available through retail pharmacies and telehealth providers.
The approval marks Lilly’s entry as the second oral GLP-1 pill on the U.S. market, following Novo Nordisk’s oral Wegovy. Industry observers are watching how the convenience of pills versus injectables will affect patient uptake and competitive dynamics between the manufacturers.
For Lilly, the authorization reinforces its position in an evolving obesity-pill market after the company surpassed Novo Nordisk in the injectable weight-loss segment. Novo Nordisk was the first to introduce GLP-1 therapies such as Ozempic for diabetes and Wegovy for obesity but has faced mounting pressure from Lilly’s offerings and from compounded alternatives of these medicines.
The approval and planned distribution schedule make Foundayo immediately relevant to several corners of the healthcare system - prescription drug manufacturers, retail pharmacy distribution channels, and telehealth providers - and will be observed for its impact on patient choice between oral and injectable options.
Context note: This report is limited to the information disclosed by Eli Lilly and the regulatory approval details announced. Where details were not provided, they are not expanded upon here.